Effect of Early Initiation of Evolocumab on Lipoprotein(a) in Patients with Acute Myocardial Infarction: Sub-Analysis of a Randomized Controlled Trial - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35621864/
Elevated circulating lipoprotein(a) levels are associated with an increased risk of cardiovascular events. We reported that early initiation of evolocumab, a proprotein convertase subtilisin/kexin type 9 inhibitor, in addition to...
Conclusion: In AMI patients, early initiation of evolocumab therapy within 24 h of primary PCI suppressed the increase in lipoprotein(a) levels within 4 weeks, regardless of baseline levels and characteristics.
Share
AFM-based nanoindentation indicates an impaired cortical stiffness in the AAV-PCSK9 DY atherosclerosis mouse model - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35648220/
Investigating atherosclerosis and endothelial dysfunction has mainly become established in genetically modified ApoE -/- or LDL-R -/- mice transgenic models. A new AAV-PCSK9DY DY mouse model with no genetic modification...
Conclusion: Our results demonstrate that this model is highly suitable and represents a good alternative to the commonly used transgenic mouse models for studying atherosclerosis and other vascular pathologies.
Share
SORBS2 as a molecular target for atherosclerosis in patients with familial hypercholesterolemia - Journal of Translational Medicine
Source : https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-022-03381-z
Background Familial hypercholesterolemia (FH) is a metabolic disease in which patients are prone to develop premature atherosclerosis (AS). Sorbin and SH3 Domain Containing 2 (SORBS2) is known to play a...
Conclusions: SORBS2 regulates lipid-induced inflammation and foam cell formation, and is a potential therapeutic target for hypercholesterolemia.
Share
Cost-Effectiveness Analysis of Evolocumab in Adult Patients with Atherosclerotic Cardiovascular Disease in Canada - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35604523/
doi: 10.1007/s12325-022-02130-4. Online ahead of print. 1 Montreal Heart Institute, Université de Montréal, Montreal, QC, Canada. 2 Health Economics and Market Access, Value Access and Policy, Amgen Canada Inc., 6775...
Conclusion: Overall, this analysis supports reimbursement of evolocumab by payers in patients with ASCVD who cannot reach LDL-C thresholds despite optimized LLT to reduce unnecessary fatal and non-fatal CV events.
Share
Undertreatment or Overtreatment With Statins: Where Are We?
Source : https://www.frontiersin.org/articles/10.3389/fcvm.2022.808712/full
Statins, in addition to healthy lifestyle interventions, are the cornerstone of lipid-lowering therapy. Other low-density lipoprotein (LDL)-lowering drugs include ezetimibe, bile acid sequestrants, and PCSK9 inhibitors. As new evidence emerges...
Relevance: This narrative review summarizes the evidence regarding the benefits of lipid-lowering drugs in reducing cardiovascular events, the pleiotropic effect of statins, real-world data on overtreatment and undertreatment of lipid-lowering therapies, and the changing LDL-C in targets in the clinical guidelines of dyslipidemias over the...
Share
-
Dr Hamid3yrseveral clinical studies have reported that, regardless of their lipid-lowering effects, statins reduce the levels of circulating pro-inflammatory molecules, such as levels of high-sensitivity C-reactive protein (hs-CRP)